Moleculin Biotech: CEO and president Walter V Klemp exercised 207,500 shares

What happened

• Walter V Klemp, CEO and president and director, exercised or converted 207,500 derivative shares on Oct 15, 2026. The filing shows an exercise/conversion (code M) for 207,500 shares (acquired) and a separate exercise/conversion (code M) for 207,500 shares (disposed) at $0.00 for $0.
• The filing reports a payment of exercise price or tax liability (code F) of 48,659 shares withheld at $0.37 per share for $18,009.
• The filing also shows two grants/awards (code A) of 415,000 derivative shares each (acquired) on Oct 15, 2026.

Key details

• Transaction date and prices: Oct 15, 2026; exercise/conversion 207,500 shares (acquired, price N/A); exercise/conversion 207,500 shares (disposed) at $0.00 for $0; tax withholding 48,659 shares at $0.37 for $18,009; grants of 415,000 and 415,000 RSU-type derivative awards (price N/A).
• Shares owned after the transaction: not reported in the provided filing excerpt.
• Relevant footnotes: F1 restricted stock units convert one-for-one into common stock; F2 shares withheld for payment of taxes upon vesting of restricted stock unit awards; F3 vesting schedule is 50% on grant and 50% in 18 equal installments over 18 months; F4 issued in connection with the reporting person's employment; F5 each restricted stock unit represents a contingent right to receive one share.
• Filing timeliness: not stated in the provided excerpt.

Why it may matter

• The filing shows conversion/exercise activity and simultaneous tax withholding: 48,659 shares were withheld to satisfy taxes, which indicates a tax-withholding (cashless) settlement rather than a separate market sale to raise cash.
• The filing also shows two new restricted stock unit awards of 415,000 shares each with a staged vesting schedule.
• A filing does not show why the insider traded or why the company acted.